**Table S1. Adjusted odds ratios for complement factors measured at 12-15 and 16-19 weeks based on multiple imputation to account for missing dataa**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Bb (12-15 weeks)b**  **N=483 subjects, 98 events** | | **Bb (16-19 weeks)c**  **N= 473 subjects, 90 events** | | **sC5b-9 (12-15 weeks)b**  **N= 483 subjects, 98 events** | | **sC5b-9 (16-19 weeks)c**  **N= 473 subjects, 90 events** | |
| **Predictor variable** | **OR (95% CI)** | **P-value** | **OR (95% CI)** | **P-value** | **OR (95% CI)** | **P-value** | **OR (95% CI)** | **P-value** |
| Non-Hispanic White (yes vs no) | 0.62 (0.36-1.07) | 0.086 | 0.63 (0.36-1.10) | 0.11 | 0.60 (0.35-1.03) | 0.064 | 0.61 (0.35-1.05) | 0.076 |
| SLE status (positive vs negative) | 1.17 (0.54-2.56) | 0.68 | 1.50 (0.66-3.43) | 0.33 | 1.10 (0.50-2.40) | 0.81 | 1.40 (0.62-3.17) | 0.42 |
| LAC status (positive vs negative) | 5.23 (2.57–10.67) | <0.0001 | 5.11 (2.44–10.72) | <0.0001 | 5.94 (2.92-12.09) | <.0001 | 6.05(2.91-12.57) | <0.0001 |
| History of thrombosis (yes vs no) | 2.91 (1.48-5.71) | 0.002 | 2.51 (1.22-5.18) | 0.013 | 2.86 (1.46-5.61) | 0.002 | 2.37 (1.17-4.81) | 0.02 |
| Diastolic pressure > 80 mm Hg  (yes vs no) | 3.52 (1.86-6.66) | 0.0001 | 3.69 (1.91-7.14) | 0.0001 | 3.43 (1.82-6.47) | 0.0001 | 3.37 (1.77-6.39) | 0.0002 |
| Aspirin Use (yes vs no) | 0.52 (0.30-0.91) | 0.021 | 0.55 (0.31-0.97) | 0.041 | 0.57 (0.33-0.99) | 0.046 | 0.57 (0.33-1.00) | 0.052 |
| Current anti-hypertensive  (yes vs no) | 3.88(1.78–8.48) | 0.0007 | 4.14 (1.87–9.17) | 0.0005 | 4.18 (1.91-9.16) | 0.0003 | 4.11 (1.89-8.94) | 0.0002 |
| BMI  < 25  25-30  > 30 | 1  1.30 (0.70-2.42)  1.83 (0.95-3.51) | 0.076 | 1  1.13 (0.54-2.19)  1.69 (0.86-3.33) | 0.15 | 1  1.365(0.71-2.56)  2.03(1.05-3.91) | 0.03 | 1  1.21(0.63-2.35)  2.04 (1.06-3.94) | 0.04 |
| Bb per SD increased | **1.32 (1.02-1.71)** | **0.032** | **1.48 (1.13-1.94)** | **0.005** | ----- |  | **----** |  |
| sC5b-9 per SD increased | ----- |  | ----- |  | **1.36 (1.05-1.76)** | **0.018** | **1.22 (0.93-1.60)** | **0.15** |
| Hosmer-Lemeshow  Goodness-of-fit test | 0.36 |  | 0.67 |  | 0.68 |  | 0.46 |  |
| AUC | 0.81 |  | 0.80 |  | 0.80 |  | 0.79 |  |
| Cross-validated AUC | 0.78 |  | 0.77 |  | 0.78 |  | 0.75 |  |

a Missing data in the predictor variables was addressed using the Markov chain Monte Carlo multiple imputation approach in the SAS procedure, PROC MI (version 9.4). Forty imputed data sets were generated for each model and results were combined with PROC MIANALYZE. Imputation model included outcome variable, predictor variables, and complement factors measured at the first three visits during pregnancy

b Subjects with APO before 15 weeks were excluded

c Subjects with APO before 19 weeks were excluded

d SD for Bb = 0.38 μg/ml at 12-15 weeks and 0.37 μg/ml at 16-19 weeks; SD for sC5b9 = 200 ng/ml at 12-15 weeks and 220 ng/ml at 16-19 weeks